Domestic innovative drugs are accelerating the embrace of the international market of the sea of stars

In recent years, thanks to the good policy and innovation environment, China's innovative drug market has been growing in size.
132.5 billion U.S. dollars in 2019 and is expected to exceed 150 billion U.S. dollars by 2021, according to the China Securities Brokerage Research Institute.
face of the fast-growing pharmaceutical market, as well as the speed of new drug approval, drug belt procurement continued to advance, domestic innovative pharmaceutical enterprises ushered in more opportunities, domestic innovative drugs are accelerating to embrace the international market star sea.
For example, on January 12th Baiji Shenzhou announced a cooperation and licensing agreement with pharmaceutical giant Novarce for the development, production and commercialization of its self-developed anti-PD-1 antibody drug, Reilly Pearl Monoanti, in several countries.
countries involved in the cooperation and authorization include the United States, Canada, Mexico, EU member states, the United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan.
the two sides will jointly develop the single anti-rejust for Reilly Pearl in the above-mentioned countries.
the product has been included in the 2020 edition of the Medicare Drug Catalog.
Again, Xinha Bio's PD-1 Xindili Monoanti and Lilly Pharmaceuticals, which will obtain a unique license from Syndicate Monodox outside China to bring the product to North America, Europe and beyond, and Xinta Bio, which will receive a cumulative payment of more than $1 billion (including a $200 million down payment and $825 million in development and sales milestone payments), will also receive a double-digit net sales increase.
expects the Syndicate to be commercialized in the U.S. by 2022-2023.
October 2020, Keystone Pharmaceuticals again authorized EQRx to develop and commercialize Shugli monoanti and PD-1 antibody CS1003 outside Greater China.
EQRx will be entitled to the exclusive commercialization rights of Shugli and C S1003 in global markets other than the Chinese mainland, Bay Area, Hong Kong Special Administrative Region and Macau Special Administrative Region.
Keystone Pharmaceuticals will retain the right to develop and commercialize the C S1003 in Greater China and will continue to explore its future as a skeleton product for monodring and combination therapies.
more domestic innovative drugs are still on their way out to sea.
, for example, Compaxip Eye Injection, a new national biologic drug that went on sale in 2014, will reduce the cost burden on patients by winning three major adaptations (nAMD, DME, pmCNV) through health care negotiations in 2019.
Based on the product's good performance in the domestic market, Compaq's eye injection manufacturer Kanghong Pharmaceuticals directly obtained a U.S. FDA Phase III clinical license, followed by Compaq's International Phase III. Phase III clinical trials in more than 30 countries and more than 300 centers around the world.
results, the product is expected to compete with foreign competitors for more than $10 billion in the eye-underlying disease market with lower price advantages and product advantages.
According to incomplete statistics, since 2020, 26 Chinese pharmaceutical companies, including Fosun Pharma, Baiji Shenzhou, Yasheng Pharmaceuticals, Renfu Pharmaceuticals, Dongsun Pharmaceuticals, Shi Pharmaceutical Group, Qilu Pharmaceuticals, etc., have obtained a total of 96 ANDA approvals in the United States, a total of 81 active ingredients.
Fosun Pharma received 22 formal approvals for its Gland Pharma.
can be seen that the domestic pharmaceutical enterprises innovation and internationalization results are gradually entering a prominent period.
believe that there will be more domestic innovative drugs out to sea in the future, highlighting the strength of the rise of domestic innovative pharmaceutical companies, and for more patients around the world to bring good news.